All In Biotech

Drug Trial Radar · NCT07188558

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

A Phase 3 Randomized Controlled Trial of Rondecabtagene Autoleucel , an Autologous, Dual-targeting CD19/CD20 CAR T-Cell Product Candidate, Vs. Investigator's Choice of CD19 CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-Cell Lymphoma in the Second-line Setting

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Jan 12, 2026

Primary completion

Dec 2029

Study completion Jan 2032

Sponsor

Lead sponsor
Lyell Immunopharma, Inc.Industry
Sponsor type
Industry
First posted
Sep 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.

Conditions

  • Large B-cell Lymphoma
  • Lymphoma, B-Cell
  • Relapsed Non-Hodgkin Lymphoma
  • Refractory Non-Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma Refractory/ Relapsed
  • Diffuse Large B Cell Lymphoma (DLBCL)
  • Diffuse Large B Cell Lymphoma Refractory
  • Diffuse Large B Cell Lymphoma Relapsed

Interventions

  • rondecabtagene autoleucelBiological

    An autologous, dual-targeting CD19/20 CAR T-cell candidate.

  • axicabtagene ciloleucelBiological

    An autologous CD19 CAR T-cell therapy

  • lisocabtagene maraleucelBiological

    An autologous CD19 CAR T-cell therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event free survivalTime frame: 36 months

Locations

44 sites in 3 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona · Recruiting

  • Honor Health

    Scottsdale, Arizona · Recruiting

  • Mayo Clinic Arizona

    Scottsdale, Arizona · Recruiting

  • University of Arkansas

    Little Rock, Arkansas · Not yet recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • University of California, Los Angeles (UCLA)

    Los Angeles, California · Recruiting

  • University of California, Irvine

    Orange, California · Recruiting

  • University of Colorado

    Aurora, Colorado · Recruiting

  • Colorado Blood Cancer Institute

    Denver, Colorado · Recruiting

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia · Recruiting

  • Mayo Clinic Florida

    Jacksonville, Florida · Recruiting

  • AdventHealth

    Orlando, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Northside Hospital

    Atlanta, Georgia · Recruiting

  • Northwestern

    Chicago, Illinois · Recruiting

  • University of Chicago

    Chicago, Illinois · Recruiting

  • University of Iowa

    Iowa City, Iowa · Recruiting

  • University of Kansas Cancer Center

    Westwood, Kansas · Recruiting

  • University of Louisville Health

    Louisville, Kentucky · Recruiting

  • Tufts Medical Center

    Boston, Massachusetts · Recruiting

  • Mayo Clinic Rochester

    Rochester, Minnesota · Recruiting

  • University of Nebraska Medical Center (UNMC)

    Omaha, Nebraska · Recruiting

  • Hackensack

    Hackensack, New Jersey · Recruiting

  • Atlantic Health

    Morristown, New Jersey · Recruiting

  • University of New Mexico Comprehensive Cancer Center

    Albuquerque, New Mexico · Recruiting

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York · Recruiting

  • Duke Cancer Institute

    Durham, North Carolina · Recruiting

  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center

    Winston-Salem, North Carolina · Not yet recruiting

  • Oncology Hematology Care Clinical Trials

    Cincinnati, Ohio · Recruiting

  • University of Cincinnati

    Cincinnati, Ohio · Recruiting

  • Cleveland Clinical Taussig Cancer Center

    Cleveland, Ohio · Recruiting

  • Allegheny Health Network

    Pittsburgh, Pennsylvania · Not yet recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • St. David's South Austin Medical Center

    Austin, Texas · Recruiting

  • University of Texas Southwestern Medical Center

    Fort Worth, Texas · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Texas Transplant Institute

    San Antonio, Texas · Recruiting

  • Intermountain Healthcare

    Salt Lake City, Utah · Recruiting

  • Virginia Oncology Associates

    Norfolk, Virginia · Recruiting

  • Virginia Commonwealth University-Massey Cancer Center

    Richmond, Virginia · Recruiting

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.